Caliway Biopharmaceuticals Co., Ltd. (6919.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$67.50 (-8.54%) as of
Key statistics
- Market cap
- 105.05B
- Forward P/E
- 12.57
- EPS (TTM)
- -0.17
- Dividend yield
- 0.00%
- 52-week range
- 66.50 – 188.00
- Beta
- 1.14
- Revenue (TTM)
- 29.39M
- Profit margin
- 0.00%
- Volume
- 11.78M
About Caliway Biopharmaceuticals Co., Ltd.
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Taipei City, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.